Physician profile
Bethany Fast
NPI 1629599873
$2,002.93
in general payments reported to CMS, 2019-2025
13 companies · $614 in 2025
The $614 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.37 · 2022: $385 · 2023: $606 · 2024: $380 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.33 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $568.67 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $290.87 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $219.80 | 2021-2025 | |
| Lundbeck LLC | $179.84 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.54 | 2022-2025 | Caplyta |
| Alkermes, INC. | $160.52 | 2023-2025 | Aristada, Lybalvi |
| Indivior INC. | $133.75 | 2022-2024 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $128.65 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $54.75 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $35.58 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $35.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Novo Nordisk INC | $14.78 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Fast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.